Literature DB >> 15182599

Markers to define ischemia: are they ready for prime time use in patients with acute coronary syndromes?

Jesse Adams1.   

Abstract

Optimal treatment of patients who present with chest pain is predicated on accurate identification of those patients with a cardiac etiology of their discomfort. Serial troponins and electrocardiograms are very sensitive for the detection of myocardial infarction but they are insensitive for the detection of ischemia. There are many analytes that are being actively evaluated for routine use to facilitate the identification of patients with myocardial ischemia. At present, only one assay is US Food and Drug Administration-approved for the exclusion of ischemia; many other analytes are under clinical evaluation and are briefly reviewed. At present, none of these analytes are yet appropriate for routine clinical use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182599     DOI: 10.1007/s11886-004-0072-1

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  23 in total

1.  Troponin I inhibits capillary endothelial cell proliferation by interaction with the cell's bFGF receptor.

Authors:  Laurie Feldman; Cecile Rouleau
Journal:  Microvasc Res       Date:  2002-01       Impact factor: 3.514

2.  Testing the wrong hypothesis: the failure to recognize the limitations of troponin assays.

Authors:  A S Jaffe
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

3.  Troponin I is present in human cartilage and inhibits angiogenesis.

Authors:  M A Moses; D Wiederschain; I Wu; C A Fernandez; V Ghazizadeh; W S Lane; E Flynn; A Sytkowski; T Tao; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Prognostic implications of elevated whole blood choline levels in acute coronary syndromes.

Authors:  Oliver Danne; Martin Möckel; Christian Lueders; Clemens Mügge; Gustav A Zschunke; Hans Lufft; Christian Müller; Ulrich Frei
Journal:  Am J Cardiol       Date:  2003-05-01       Impact factor: 2.778

Review 5.  Inflammation and atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Attilio Maseri
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

6.  Soluble CD40 ligand in acute coronary syndromes.

Authors:  Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Marcel J van den Brand; Eric Boersma; Andreas M Zeiher; Maarten L Simoons
Journal:  N Engl J Med       Date:  2003-03-20       Impact factor: 91.245

7.  Soluble CD40L: risk prediction after acute coronary syndromes.

Authors:  Nerea Varo; James A de Lemos; Peter Libby; David A Morrow; Sabina A Murphy; Rebecca Nuzzo; C Michael Gibson; Christopher P Cannon; Eugene Braunwald; Uwe Schönbeck
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

8.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.

Authors:  E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-31       Impact factor: 91.245

9.  Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease.

Authors:  Stefan Blankenberg; Hans J Rupprecht; Christoph Bickel; Michael Torzewski; Gerd Hafner; Laurence Tiret; Marek Smieja; François Cambien; Jürgen Meyer; Karl J Lackner
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

10.  Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation.

Authors:  Juha Lund; Qiu-Ping Qin; Tuomo Ilva; Kim Pettersson; Liisa-Maria Voipio-Pulkki; Pekka Porela; Kari Pulkki
Journal:  Circulation       Date:  2003-10-06       Impact factor: 29.690

View more
  1 in total

1.  The PRIMA study: presentation ischaemia-modified albumin in the emergency department.

Authors:  L Keating; J R Benger; R Beetham; S Bateman; S Veysey; J Kendall; R Pullinger
Journal:  Emerg Med J       Date:  2006-10       Impact factor: 2.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.